History

Arrhythmia Research Technology, Inc. (ART) was founded in 1981 specifically to capitalize on the marketing of certain patents or licenses concerning the application of signal-averaged electrocardiography (SAECG) for the detection of cardiac late potentials.

Late potentials have been shown to be an indicator of risk for ventricular tachycardia (VT) which can degenerate into ventricular fibrillation and result in the sudden cardiac death syndrome, especially in post myocardial infarction patients. Sudden cardiac death afflicts over 400,000 individuals in the United States alone each year.

Today, ART's SAECG products are used by major research institutions, hospitals and clinics throughout the world. In fact, the majority of all scientific and medical literature written about SAECG used the ART 1200EPX™ and PREDICTOR® product lines of signal-averaging systems! These systems and product lines have defined the industry and clinical standards for high resolution electrocardiography.

ART is committed to growth by the development and acquisition of emerging technologies, finding the best and brightest people, and world class customer service.

"Signal averaged ECG with detailed analysis of QRS duration and late potentials is a very valuable tool in stratifying patients at risk of cardiac death. MADIT II type patients with normal QRS duration and lack of late potentials are at relatively low risk of subsequent cardiac events. The very high negative predictive value of SAECG might help prioritize patients for ICD therapy. We are glad to have the opportunity to test the predictive value of SAECG in a prospective cohort of MADIT II type patients who are undergoing several other tests simultaneously. It is likely that SAECG and Microvolt T-Wave Alternans tests will emerge as routine for identifying low-risk and high-risk patients considered for ICD therapy."

Wojciech Zareba, MD, PhD, University of Rochester Medical School

Principal Investigator for National Institutes for Health funded investigation into "Risk Stratification in MADITT II Type Patients".